Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05484206
PHASE1

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Sponsor: Vir Biotechnology, Inc.

View on ClinicalTrials.gov

Summary

In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.

Official title: A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

144

Start Date

2022-09-21

Completion Date

2027-04-30

Last Updated

2025-06-13

Healthy Volunteers

Yes

Interventions

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection.

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection.

Locations (5)

Inland Empire Clinical Trials

Rialto, California, United States

Orange County Research Center

Tustin, California, United States

CenExel Research Centers of America

Hollywood, Florida, United States

Floridian Clinical Research

Miami Lakes, Florida, United States

Texas Liver Institute

San Antonio, Texas, United States